NeurogesX, a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced the terms of its IPO Tuesday. The company plans to offer 4 million shares at $13.00 to $15.00 per share. Morgan Stanley is the lead manager on the deal.
